EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population

Jonathan Corren, Stanley J Szefler, Ellen Sher, Phillip Korenblat, Weily Soong, Nicola A Hanania, Gary Berman, Guy Brusselle, Ralph Zitnik, Chitra R Natalie, Luna Sun, Kimberly Siu und 3 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2024-05 · 12 (5) · 1215-1224.e3

DOI: 10.1016/j.jaip.2024.02.007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-05. Verfasst von Jonathan Corren und 14 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at UCLA, Los Angeles, Calif. Electronic address: jcorren@ucla.edu. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Eosinophils. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: LAVOLTA (L)I, LII, and ACOUSTICS were randomized, placebo-controlled, Phase 3 trials of lebrikizumab, a monoclonal antibody targeting IL-13 in patients with uncontrolled asthma. Failure to demonstrate efficacy may have been related to patient selection in those trials. OBJECTIVE: To assess the efficacy in a well-defined subpopulation of patients with elevated blood eosinophil counts and a minimum number of prior asthma exacerbations. We performed an additional analysis in a subpopulation of patients with elevated FeNO and prior exacerbations. METHODS: Adult (LI and LII) and adolescent patients (aged 12-17 years weighing ≥40 kg, ACOUSTICS) with uncontrolled asthma received lebrikizumab (125 mg, n = 832; or 37.5 mg, n = 829) or placebo (n = 833) subcutaneously every 4 weeks. Post hoc analysis of the annualized adjusted exacerbation rate (AER) was performed in a subpopulation of patients with baseline blood eosinophils of 300 cells/μL or greater and history of one or more exacerbations. In this subpopulation, there were 227 patients in the placebo group, 222 in the lebrikizumab 37.5-mg group, and 217 in the lebrikizumab 125-mg group. We summarized safety in patients who received at least one dose of lebrikizumab using adverse events. RESULTS: Lebrikizumab significantly reduced AER compared with placebo in adults (AER reduction: 125 mg [38%]; and 37.5 mg [41%]) and adolescents (AER reduction:125 mg [59%]; 37.5 mg [64%]) with baseline blood eosinophils of 300 cells/μL or greater and one or more exacerbations. Most adverse events were mild or moderate in severity and did not lead to treatment discontinuation. CONCLUSION: Lebrikizumab significantly reduced asthma exacerbations in a subpopulation of patients with elevated blood eosinophils, elevated FeNO, and a history of asthma exacerbation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsEosinophilsHumansAdolescentMaleChildFemaleAdultAntibodies, MonoclonalMiddle AgedYoung AdultInterleukin-13Nitric OxideLeukocyte CountTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

Allergic asthmaEfficacyIL-13LebrikizumabPost hoc analysisSafety

Substanzen

lebrikizumabAnti-Asthmatic AgentsAntibodies, MonoclonalInterleukin-13Nitric Oxide

Autor:innen und Institutionen

  • David Geffen School of Medicine at UCLA, Los Angeles, Calif. Electronic address: jcorren@ucla.edu.
  • Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.
  • Allergy Partners of NJ, Ocean, NJ.
  • Phillip Korenblat LLC, St Louis, Mo.
  • Allervie Clinical Research-Alabama Allergy & Asthma Center, Birmingham, Ala.
  • Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Corren, J., Szefler, S. J., Sher, E., Korenblat, P., Soong, W., Hanania, N. A., Berman, G., Brusselle, G., Zitnik, R., Natalie, C. R., Sun, L., Siu, K., Wu, W. S., Lio, P., & Armstrong, A. W. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology: In Practice, 12(5), 1215-1224.e3. https://doi.org/10.1016/j.jaip.2024.02.007

Vancouver

Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, et al. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(5):1215-1224.e3. doi:10.1016/j.jaip.2024.02.007

BibTeX
@article{Corren2024,
  author = {Corren, Jonathan and Szefler, Stanley J and Sher, Ellen and Korenblat, Phillip and Soong, Weily and Hanania, Nicola A and Berman, Gary and Brusselle, Guy and Zitnik, Ralph and Natalie, Chitra R and Sun, Luna and Siu, Kimberly and Wu, Wen-Shuo and Lio, Peter and Armstrong, April W},
  title = {Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {1215--1224.e3},
  doi = {10.1016/j.jaip.2024.02.007}
}
Kostenlos starten →